SCHEMBL4734282

SCHEMBL4734282

C[C@H]1C[C@]2(CCN1C(=O)O)C(=N)NC(=O)N2c1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.41
BACE2 Q9Y5Z0 1/20 0.40
ADAMTS5 Q9UNA0 9/20 0.36
MMP2 P08253 4/20 0.36
MMP14 P50281 3/20 0.36
MMP13 P45452 1/20 0.36
ALOX5 P09917 1/20 0.35
METAP2 P50579 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
PLD2 O14939 2/20 0.34
PLD1 Q13393 2/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5305865 1.00 BACE1 (0.41) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL10262712 0.86 BACE1 (0.43) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL755093 0.86 BACE1 (0.43) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL3479505 0.85 MCHR1 (0.41) ADAMTS5ALOX5METAP2OPRM1
SCHEMBL14248524 0.82 ADAMTS5 (0.36) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL3893080 0.80 MAPK14 (0.39) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL3479516 0.80 MAPK14 (0.39) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL4249026 0.79 KCNJ6 (0.35) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL3479619 0.79 KCNJ6 (0.35) BACE1BACE2ADAMTS5MMP2MMP14
SCHEMBL10263218 0.78 ALOX5 (0.42) BACE1BACE2ADAMTS5ALOX5OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211904-B2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease Merck, Sharp & Dohme Corp. (US) 2012-07-03 US disclosed
EP-1910364-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2008-04-16 EP disclosed
WO-2007011833-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2007-01-25 US disclosed
WO-2007011810-A1 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021454-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease BACE1, APP, PSEN1 BACE1 1/4885BACE2 4/4885ADAMTS5 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.